skip to content »

Translational Biology & Molecular Medicine

Houston, Texas

Benchtop, Research, Bedside and Application
Translational Biology & Molecular Medicine Graduate Program
not shown on screen

Rachel Schiff, Ph.D.

Rachel Schiff

Associate Professor
Department of Medicine-Hematology/Oncology
Smith Breast Center

Phone: 713-798-1676
Fax: 713-798-1659
Lab Web Site: Osborne-Schiff Lab


  • Ph.D., Department of Virology, The Hebrew University, Hadassah Medical School, Jerusalem, Israel

Research Interests

  • Breast cancer endocrine and targeted therapies

Selected Publications

  • Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006. 98:315-27.
  • Schiff R, Lee AV. Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators? Nat Clin Pract Oncol. 2006. 3:134-5.
  • Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005. 97:1254-61.
  • Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. Journal of Clinical Oncology. 2005. 23:7721-35.
  • Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer. 2005. 12 Suppl 1:S113-7.
  • Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005. 14:458-65.
  • Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemotherapy and Pharmacology. 2005. 56:10-20.

E-mail this page to a friend